These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32800727)

  • 1. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer.
    Schaid DJ; McDonnell SK; FitzGerald LM; DeRycke L; Fogarty Z; Giles GG; MacInnis RJ; Southey MC; Nguyen-Dumont T; Cancel-Tassin G; Cussenot O; Whittemore AS; Sieh W; Ioannidis NM; Hsieh CL; Stanford JL; Schleutker J; Cropp CD; Carpten J; Hoegel J; Eeles R; Kote-Jarai Z; Ackerman MJ; Klein CJ; Mandal D; Cooney KA; Bailey-Wilson JE; Helfand B; Catalona WJ; Wiklund F; Riska S; Bahetti S; Larson MC; Cannon Albright L; Teerlink C; Xu J; Isaacs W; Ostrander EA; Thibodeau SN
    Eur Urol; 2021 Mar; 79(3):353-361. PubMed ID: 32800727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
    Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
    Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.
    Darst BF; Saunders E; Dadaev T; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Wang Y; Patel AV; Albanes D; Weinstein SJ; Gnanapragasam V; Huff C; Couch FJ; Wolk A; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz MM; Schmidt JA; Travis RC; Key TJ; Stopsack KH; Mucci LA; Catalona WJ; Marosy B; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Conti DV; Kote-Jarai Z; Haiman CA
    JAMA Oncol; 2023 Nov; 9(11):1514-1524. PubMed ID: 37733366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
    Leongamornlert DA; Saunders EJ; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Benafif S; Brook MN; Donovan JL; Hamdy FC; Neal DE; Muir K; Govindasami K; Conti DV; Kote-Jarai Z; Eeles RA
    Eur Urol; 2019 Sep; 76(3):329-337. PubMed ID: 30777372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes.
    Karyadi DM; Geybels MS; Karlins E; Decker B; McIntosh L; Hutchinson A; Kolb S; McDonnell SK; Hicks B; Middha S; FitzGerald LM; DeRycke MS; Yeager M; Schaid DJ; Chanock SJ; Thibodeau SN; Berndt SI; Stanford JL; Ostrander EA
    Oncotarget; 2017 Jan; 8(1):1495-1507. PubMed ID: 27902461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational landscape of candidate genes in familial prostate cancer.
    Johnson AM; Zuhlke KA; Plotts C; McDonnell SK; Middha S; Riska SM; Schaid DJ; Thibodeau SN; Douglas JA; Cooney KA
    Prostate; 2014 Oct; 74(14):1371-8. PubMed ID: 25111073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
    Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population.
    Oh JJ; Lee SJ; Hwang JY; Kim D; Lee SE; Hong SK; Ho JN; Yoon S; Sung J; Kim WJ; Byun SS
    Oncotarget; 2017 Jul; 8(27):43934-43943. PubMed ID: 28380453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients.
    Na R; Wei J; Sample CJ; Gielzak M; Choi S; Cooney KA; Rabizadeh D; Walsh PC; Zheng LS; Xu J; Isaacs WB
    Br J Cancer; 2022 Mar; 126(5):791-796. PubMed ID: 34799695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.
    Chen F; Madduri RK; Rodriguez AA; Darst BF; Chou A; Sheng X; Wang A; Shen J; Saunders EJ; Rhie SK; Bensen JT; Ingles SA; Kittles RA; Strom SS; Rybicki BA; Nemesure B; Isaacs WB; Stanford JL; Zheng W; Sanderson M; John EM; Park JY; Xu J; Wang Y; Berndt SI; Huff CD; Yeboah ED; Tettey Y; Lachance J; Tang W; Rentsch CT; Cho K; Mcmahon BH; Biritwum RB; Adjei AA; Tay E; Truelove A; Niwa S; Sellers TA; Yamoah K; Murphy AB; Crawford DC; Patel AV; Bush WS; Aldrich MC; Cussenot O; Petrovics G; Cullen J; Neslund-Dudas CM; Stern MC; Kote-Jarai Z; Govindasami K; Cook MB; Chokkalingam AP; Hsing AW; Goodman PJ; Hoffmann TJ; Drake BF; Hu JJ; Keaton JM; Hellwege JN; Clark PE; Jalloh M; Gueye SM; Niang L; Ogunbiyi O; Idowu MO; Popoola O; Adebiyi AO; Aisuodionoe-Shadrach OI; Ajibola HO; Jamda MA; Oluwole OP; Nwegbu M; Adusei B; Mante S; Darkwa-Abrahams A; Mensah JE; Diop H; Van Den Eeden SK; Blanchet P; Fowke JH; Casey G; Hennis AJ; Lubwama A; Thompson IM; Leach R; Easton DF; Preuss MH; Loos RJ; Gundell SM; Wan P; Mohler JL; Fontham ET; Smith GJ; Taylor JA; Srivastava S; Eeles RA; Carpten JD; Kibel AS; Multigner L; Parent MÉ; Menegaux F; Cancel-Tassin G; Klein EA; Andrews C; Rebbeck TR; Brureau L; Ambs S; Edwards TL; Watya S; Chanock SJ; Witte JS; Blot WJ; Michael Gaziano J; Justice AC; Conti DV; Haiman CA
    Eur Urol; 2023 Jul; 84(1):13-21. PubMed ID: 36872133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma.
    Kibel AS; Ahn J; Isikbay M; Klim A; Wu WS; Hayes RB; Isaacs WB; Daw EW
    Prostate; 2016 Apr; 76(5):479-90. PubMed ID: 26708993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
    Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
    Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
    Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.
    Darst BF; Dadaev T; Saunders E; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Gapstur SM; Stevens V; Albanes D; Weinstein SJ; Gnanapragasam V; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz M; Schmidt JA; Mucci L; Catalona WJ; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Kote-Jarai Z; Conti DV; Haiman CA
    J Natl Cancer Inst; 2021 May; 113(5):616-625. PubMed ID: 32853339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.
    Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
    Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.
    Hunter SM; Rowley SM; Clouston D; ; Li J; Lupat R; Krishnananthan N; Risbridger G; Taylor R; Bolton D; Campbell IG; Thorne H
    Urol Oncol; 2016 Mar; 34(3):120.e9-16. PubMed ID: 26585945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.